Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 5/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13887001 | 0.90 | CACNA1H (0.54) | CACNA1HCACNA1BCACNA1CTACR1MTOR | |
| SCHEMBL27732549 | 0.87 | MTOR (0.46) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL21448062 | 0.87 | KDM4A (0.46) | KDM4AL3MBTL1GRM2HDAC1NAMPT | |
| SCHEMBL22702229 | 0.87 | KDM4A (0.46) | KDM4AL3MBTL1GRM2HDAC1NAMPT | |
| SCHEMBL13818148 | 0.85 | CACNA1H (0.50) | CACNA1HCACNA1BCACNA1CTACR1MTOR | |
| SCHEMBL24971038 | 0.84 | CACNA1H (0.52) | CACNA1HCACNA1BCACNA1CTACR1MTOR | |
| SCHEMBL31143037 | 0.84 | CACNA1H (0.52) | CACNA1HCACNA1BCACNA1CTACR1MTOR | |
| SCHEMBL14169755 | 0.84 | CACNA1H (0.49) | CACNA1HCACNA1BCACNA1CTACR1MTOR | |
| SCHEMBL27377175 | 0.83 | GRM2 (0.45) | CACNA1HCACNA1BCACNA1CKDM4AL3MBTL1 | |
| SCHEMBL545480 | 0.83 | CACNA1H (0.48) | CACNA1HCACNA1BCACNA1CTACR1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| CN-101365682-A | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARM INC (US) | 2009-02-11 | — | — | CN | disclosed |
| US-7390803-B2 | Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | CACNA1H 4399/4885CACNA1B 3618/4885CACNA1C 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.